4 results on '"Halperin, Jose A."'
Search Results
2. Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes.
- Author
-
Meek, Claire L., Tundidor, Diana, Feig, Denice S., Yamamoto, Jennifer M., Scott, Eleanor M., Ma, Diane D., Halperin, Jose A., Murphy, Helen R., Corcoy, Rosa, and CONCEPTT Collaborative Group
- Subjects
TYPE 1 diabetes ,PREGNANCY outcomes ,BIOMARKERS ,GESTATIONAL diabetes ,PREMATURE labor ,RESEARCH ,BLOOD sugar monitoring ,RESEARCH methodology ,BLOOD sugar ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding - Abstract
Objective: The optimal method of monitoring glycemia in pregnant women with type 1 diabetes remains controversial. This study aimed to assess the predictive performance of HbA1c, continuous glucose monitoring (CGM) metrics, and alternative biochemical markers of glycemia to predict obstetric and neonatal outcomes.Research Design and Methods: One hundred fifty-seven women from the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT) were included in this prespecified secondary analysis. HbA1c, CGM data, and alternative biochemical markers (glycated CD59, 1,5-anhydroglucitol, fructosamine, glycated albumin) were compared at ∼12, 24, and 34 weeks' gestation using logistic regression and receiver operating characteristic (ROC) curves to predict pregnancy complications (preeclampsia, preterm delivery, large for gestational age, neonatal hypoglycemia, admission to neonatal intensive care unit).Results: HbA1c, CGM metrics, and alternative laboratory markers were all significantly associated with obstetric and neonatal outcomes at 24 weeks' gestation. More outcomes were associated with CGM metrics during the first trimester and with laboratory markers (area under the ROC curve generally <0.7) during the third trimester. Time in range (TIR) (63-140 mg/dL [3.5-7.8 mmol/L]) and time above range (TAR) (>140 mg/dL [>7.8 mmol/L]) were the most consistently predictive CGM metrics. HbA1c was also a consistent predictor of suboptimal pregnancy outcomes. Some alternative laboratory markers showed promise, but overall, they had lower predictive ability than HbA1c.Conclusions: HbA1c is still an important biomarker for obstetric and neonatal outcomes in type 1 diabetes pregnancy. Alternative biochemical markers of glycemia and other CGM metrics did not substantially increase the prediction of pregnancy outcomes compared with widely available HbA1c and increasingly available CGM metrics (TIR and TAR). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
3. Emerging Protein Biomarkers for the Diagnosis or Prediction of Gestational Diabetes—A Scoping Review.
- Author
-
Bogdanet, Delia, Reddin, Catriona, Murphy, Dearbhla, Doheny, Helen C., Halperin, Jose A., Dunne, Fidelma, O'Shea, Paula M., and Benhalima, Katrien
- Subjects
GESTATIONAL diabetes ,HYPERGLYCEMIA ,GLUCOSE tolerance tests ,TYPE 2 diabetes ,PREGNANCY outcomes ,BIOMARKERS - Abstract
Introduction: Gestational diabetes (GDM), defined as hyperglycemia with onset or initial recognition during pregnancy, has a rising prevalence paralleling the rise in type 2 diabetes (T2DM) and obesity. GDM is associated with short-term and long-term consequences for both mother and child. Therefore, it is crucial we efficiently identify all cases and initiate early treatment, reducing fetal exposure to hyperglycemia and reducing GDM-related adverse pregnancy outcomes. For this reason, GDM screening is recommended as part of routine pregnancy care. The current screening method, the oral glucose tolerance test (OGTT), is a lengthy, cumbersome and inconvenient test with poor reproducibility. Newer biomarkers that do not necessitate a fasting sample are needed for the prompt diagnosis of GDM. The aim of this scoping review is to highlight and describe emerging protein biomarkers that fulfill these requirements for the diagnosis of GDM. Materials and Methods: This scoping review was conducted according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines for scoping reviews using Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing & Allied Health Literature (CINAHL), PubMed, Embase and Web of Science with a double screening and extraction process. The search included all articles published in the literature to July 2020. Results: Of the 3519 original database citations identified, 385 were eligible for full-text review. Of these, 332 (86.2%) were included in the scoping review providing a total of 589 biomarkers studied in relation to GDM diagnosis. Given the high number of biomarkers identified, three post hoc criteria were introduced to reduce the items set for discussion: we chose only protein biomarkers with at least five citations in the articles identified by our search and published in the years 2017–2020. When applied, these criteria identified a total of 15 biomarkers, which went forward for review and discussion. Conclusions: This review details protein biomarkers that have been studied to find a suitable test for GDM diagnosis with the potential to replace the OGTT used in current GDM screening protocols. Ongoing research efforts will continue to identify more accurate and practical biomarkers to take GDM screening and diagnosis into the 21st century. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Plasma glycated CD59, a novel biomarker for the prediction, diagnosis, and follow-up of women with gestational diabetes
- Author
-
Bogdanet, Delia, Dunne, Fidelma, O'Shea, Paula, Halperin, Jose, Luque Fernandez, Miguel Angel, and Irish Clinical Academic Training Programme
- Subjects
postpartum glucose intolerance ,pregnancy outcomes ,Medicine ,plasma glycated CD59 ,Gestational diabetes ,Medicine, Nursing and Health Sciences - Abstract
The prevalence of gestational diabetes (GDM) is rising worldwide. Plasma glycated CD59 (pGCD59) is an emerging biomarker for the detection of hyperglycaemia. The aim of this study was to explore the ability of pGCD59 to predict and/or identify GDM diagnosed at 24-28 weeks of gestation by a 2h 75g oral glucose tolerance test (OGTT), the ability of pGCD59 to predict post-partum glucose intolerance (GI) diagnosed by a 2h 75 g OGTT and the ability of pGCD59 to predict adverse pregnancy outcomes. This was a prospective study of pregnant women with no prior diagnosis of diabetes. Samples for pGCD59 were collected at the first antenatal appointment (T1), at the time of the OGTT (T2) and post-partum (PP). The ability of pGCD59 to predict a diagnosis of GI was assessed using nonparametric receiver operating characteristic (ROC) curves. This study found that T1 and T2 pGCD59 levels are a fair predictor of GDM status diagnosed by an elevated fasting plasma glucose (FPG) and a very good predictor of GDM status in subjects with very high BMI. Furthermore, this study showed that T1 and T2 levels of pGCD59 can predict the development of early PP GI with fair accuracy and that PP levels of pGCD59 can identify women with PP GI with good accuracy. T1 and T2 pGCD59 levels showed likely potential in predicting the development of adverse pregnancy outcomes. The observations made within this thesis extend the current knowledge on the utility of pGCD59 in pregnancy. Future studies with a focus on investigating the dynamic between pGCD59 levels-GDM and risk factors (ethnicity, high BMI, gestational weight changes etc.) are required to fully explore and validate the true potential of pGCD59. The inclusion of cohorts with a significantly larger number of adverse pregnancy outcomes will potentially substantiate our findings and extend the utility of pGCD59 in clinical practice.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.